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2Research in context23
Evidence before this study24
We searched Pubmed for articles published in English before December 4, 2016, using the terms25
“Parkinson’s disease”, “glucagon-like peptide-1”, “exenatide”, “trial”, “neuroprotection” and26
“disease modification” in any field. We found several pre-clinical studies of exenatide, a glucagon-27
like peptide-1 agonist, which demonstrated neuroprotective and neurorestorative effects in28
experimental animal-toxin models of Parkinson’s disease. We identified a single “proof-of-concept”29
study evaluating exenatide as a possible disease modifying treatment in patients with Parkinson’s30
disease. In this open-label trial, 21 patients randomised to receive 12 months of exenatide injections31
in addition to their regular medication demonstrated a mean improvement of 2.7 points on the32
MDS-UPDRS Part 3 OFF medication, compared to a decline of 2.2 points in 24 patients in the control33
group that received their regular medication only (mean difference 4.9 points, 95% CI, 0.3-9.4;34
p=0.037). In addition, patients treated with exenatide had a significant improvement of 2.2 points35
on a cognitive assessment scale (the Mattis-DRS-2) in comparison to a decline of 2.8 points in the36
control group (mean difference 5.0 points, 95% CI, 9.2-0.8; p=0.006). There were persistent37
statistically significant benefits in the exenatide group versus controls in motor disability as assessed38
by the MDS-UPDRS Part 3 OFF score (5.6 points, 95% CI, 2.2 – 9.0; p = 0.002) and cognitive function39
as assessed by the Mattis-DRS-2 (5.3 points, 95% CI, 9.3–1.4; p = 0.006) 12 months after the40
withdrawal of exenatide; however, due to the lack of a placebo control, these data could not be41
interpreted as proof of efficacy.42
Added value of this study43
Our study is the first randomised, placebo-controlled trial of exenatide as a potential disease44
modifying agent in Parkinson’s disease. After 48 weeks, patients treated with 2mg exenatide once-45
weekly had a significant advantage on the primary outcome measure- the MDS-UPDRS Part 3 scale46
compared to the placebo group, which persisted as a statistically significant advantage following the47
end of the drug washout period 12 weeks later. Our study is also the first to demonstrate that48
3exenatide administered at a dose licensed for treatment in diabetes, can cross the blood brain49
barrier in humans and is detectable in the CSF in concentrations not dissimilar from those in pre-50
clinical PD models associated with advantageous outcomes. Exenatide was well tolerated, although51
injection site reactions and gastrointestinal symptoms were reported.52
Implications of all the available evidence53
We have replicated the results of our previous clinical study and demonstrated that patients treated54
with exenatide had positive effects on the practically defined off-medication motor scores of55
Parkinson’s disease in comparison to the placebo group, and that these effects were sustained at56
least partially beyond the period of exposure. Whether exenatide impacts the underlying57
pathophysiology of Parkinson’s disease or simply induces long lasting symptomatic effects remains58
uncertain, however these results represent a major new avenue for investigation in the treatment of59
Parkinson’s disease.60
61
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4Summary63
Background64
Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist has neuroprotective effects in pre-65
clinical models of Parkinson’s disease (PD).66
Methods67
In this single-centre, randomised, double-blind, placebo-controlled trial, patients with moderate68
stage PD were randomly assigned (1:1) to receive subcutaneous injections of exenatide 2mg once-69
weekly or matched placebo for 48 weeks in addition to their regular medication. Randomisation was70
by web-based randomisation service with a two strata block design according to PD severity.71
Patients and investigators were blinded to treatment allocation. The primary outcome was the72
adjusted difference in the Movement-Disorders-Society-Unified-Parkinson's-Disease-Rating-Scale73
(MDS-UPDRS) motor subscale (Part 3) in the practically defined OFF medication state at 60 weeks74
(i.e. following a 12 week exenatide washout period). The study is registered at Clinicaltrials.gov75
(NCT01971242).76
Findings77
62 patients were enrolled between 18 June 2014, and March 13, 2015. The primary analysis included78
29 patients in the placebo group and 31 patients in the exenatide group. At 60 weeks patients in the79
placebo group had declined by 2.1 (95%CI -0.6, 4.8) points from baseline while the exenatide group80
improved by 1.0 (95%CI -2.6, 0.7) – a mean difference of 3.5 points (95%CI -6.7 to -0.3, p=0.0318)81
favouring the exenatide group. Injection site reactions and gastrointestinal symptoms were common82
adverse events in both groups. There were 8 serious adverse events; 6 in the exenatide group and 283
in the placebo group though none were judged to be related to the study interventions.84
Interpretation85
5Patients treated with exenatide had positive effects on the practically defined off-medication motor86
scores of PD in comparison to the placebo group, that were sustained beyond the period of87
exposure. Whether exenatide impacts the underlying disease pathophysiology or simply induces88
long lasting symptomatic effects is uncertain, however these results suggest that exenatide89
represents a major new avenue for investigation in the treatment of PD, and effects on everyday90
symptoms should be performed in future longer term trials.91
Funding92
Michael J. Fox Foundation for Parkinson’s Research.93
94
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INTRODUCTION96
Perhaps the most important unmet need in Parkinson’s disease (PD) is the development of a97
neuroprotective or disease-modifying therapy that may slow or halt disease progression. To date98
none of the compounds that have indicated potential neuroprotective properties in in-vitro or99
animal models have conclusively demonstrated any effects on disease progression in clinical trials1.100
Glucagon-like peptide-1 (GLP-1) agonists are licensed for the treatment of Type 2 diabetes. These101
agents activate GLP-1 receptors to promote glucose-level-dependent insulin secretion, inhibit102
glucagon secretion and slow gastric emptying2. Exenatide is a synthetic version of exendin-4, a103
naturally occurring analog of human GLP-1 originally discovered in the saliva of the Gila monster104
(Heloderma suspectum), and resistant to the normal metabolic processes that degrade endogenous105
human GLP-13. In addition to effects on glucose homeostasis, evidence from toxin-based rodent106
models of PD demonstrate that exenatide crosses the blood-brain-barrier and exerts107
neuroprotective and neurorestorative effects, mediated via GLP-1 receptors, at doses comparable to108
those used to treat Type 2 diabetes, resulting in improvements in motor performance, behaviour,109
learning and memory4–8.110
We previously conducted a small, proof of concept, open label trial of exenatide in moderate111
severity PD patients. Twelve months exposure to exenatide led to improvements in motor and112
cognitive assessments compared to the control group9, which persisted 12 months following drug113
withdrawal10. Based on these encouraging observations, our primary aim was to conduct a114
randomised, placebo-controlled trial (Clinical trials.gov Identifier NCT01971242) to further assess the115
potential disease modifying effects of 48 weeks exposure to exenatide followed by a 12 week116
exenatide washout, on the motor severity of PD.117
118
METHODS119
7Study Design120
This study was a randomised, double blind, placebo controlled, single centre, 60 week trial of121
exenatide once weekly for the treatment of moderate severity PD. The trial utilised a parallel-group,122
“washout” design, comprising an initial 48-week exposure period to exenatide 2mg subcutaneous123
injection once-weekly, or matched placebo, followed by study drug withdrawal and a final124
assessment 12 weeks later. The study was co-ordinated by the UCL Comprehensive Clinical Trials125
Unit. Clinical oversight of the trial was provided by a trial steering committee, an independent data126
and safety monitoring board and was approved by the local ethics committee. Trial operations were127
supported by the Leonard Wolfson Experimental Neuroscience Centre and the National Institute of128
health research (NIHR) Biomedical Research Centre at the UCL Institute of Neurology and UCLH-129
National Hospital for Neurology and Neurosurgery, London, UK.130
Patients131
Eligible patients were men and women aged between 25 and 75 years old with idiopathic PD based132
on Queen Square Brain Bank criteria11, were on dopaminergic treatment with wearing off133
phenomena, and were at Hoehn and Yahr stage 2.5 or less when on PD medication. Key exclusion134
criteria (See trial protocol for full list) included concurrent dementia (defined as score <120 points on135
the Mattis-Dementia Rating scale (DRS-2) and patients with Body mass index <18.5. Patients with136
diabetes (glycated haemoglobin [HbA1c] ≥ 48mmol/l at screening) were also excluded.  All patients 137 
signed a written informed consent before entry into the study.138
Randomisation139
Randomisation was by a web-based randomisation service (Sealedenvelope.com) with a block design140
of two strata according to PD severity (H&Y 1.0-2.0 and H&Y 2.5). Patients were randomised (1:1) to141
self-administer exenatide once weekly 2mg subcutaneous injections or matched placebo injections,142
in addition to their regular medications. Unique 3 digit identifiers for every active/placebo drug kit143
were generated by the trial statistician and uploaded to Sealedevenlope.com in order to allow144
allocation of masked study drug kits (sufficient for 12 weeks) at randomisation and follow up visits145
8by assessing clinicians. Patients and investigators were blinded to treatment allocation throughout146
the study. Exenatide and matched placebo injection kits were provided by Astra Zeneca and were147
identical in appearance. Empty drug vials and questionnaires were collected at each visit to assess148
compliance.149
Study procedures150
At screening, each patient had a physical and neurological examination, assessments of mood and151
cognition, blood sampling for clinical laboratory tests and a pregnancy test for women of152
childbearing potential. Electrocardiogram and [¹²³I]FP-CIT SPECT (Datscan) imaging were also153
performed. Following confirmation of patient eligibility, subsequent visits were performed at154
baseline (0) and at weeks 12, 24, 36, 48 and 60. Patients were supplied with study drug kits sufficient155
for 12 weeks and instructed how to assemble and self-administer the once-weekly, subcutaneous156
injections. At each visit, patients attended in the OFF medication state – defined as a period of157
withdrawal of levodopa for at least 8 hours (overnight) or 36 hours in the case of longer acting158
agents such as ropinirole, pramipexole, rasagiline or rotigotine. Patients were evaluated with the159
Movement Disorders Society Unified Parkinson’s Disease rating Scale (MDS-UPDRS) and timed motor160
tests (10m timed walk, timed keyboard taps in 30 seconds utilising a novel web based program –161
Braintaptest.com) by a dedicated trial team. They also had repeat motor assessments approximately162
1 hour after taking their regular PD medications (to allow uniformity across patients) alongside163
assessments of cognition, dyskinesia, quality of life, mood and non-motor symptoms.164
After 48 weeks, study drugs were withdrawn. A final clinical assessment and repeat Datscan imaging165
was performed at 60 weeks. Blood and urine were collected at each visit and cerebrospinal fluid was166
collected at week 12 and 48 for exenatide pharmacokinetic measurements. Changes in concurrent167
medication were permitted throughout the trial period (to minimise patient drop out) and the168
levodopa equivalent dose (LED) was calculated at each visit12. To prevent the possibility of adverse169
events compromising rater blinding, all adverse events, biochemical results, vital signs (blood170
9pressure and heart rate) and weight were recorded separately, by clinicians also blinded to171
treatment allocation.172
Outcomes173
The primary outcome was to compare the difference in MDS-UPDRS Part 3 score in the practically174
defined OFF medication state at 60 weeks, according to treatment allocation. Predefined secondary175
outcomes were the differences between exenatide and placebo in each subsection of the MDS-176
UPDRS in the ON states and the Mattis DRS-2 at both the 48 and 60 week time-points. Additional177
secondary measures included adverse event frequency, changes in vital signs, weight and clinical178
laboratory values. Exploratory outcomes included the differences between groups in; dopamine179
transporter availability as measured by Datscan13; timed motor tests in both OFF and ON states; the180
Unified Dyskinesia Rating Scale (UDysRS); Montgomery and Asberg Depression Rating Scale181
(MADRS); Non-Motor Symptoms severity scale (NMSS); the Parkinson’s disease questionnaire-39182
(PDQ39); 3 day Hauser diary of PD state; EuroQol five dimensions questionnaire (EQ-5D)-3L and183
levodopa equivalent dose (LED).184
Statistical Analysis185
All study analyses were performed according to a predefined Statistical Analysis plan using186
STATA/MP (StataCorp, Version 14.1 MP, College Station, TX, USA) and SPSS (IBM, Version 21.0.187
Armonk, NY: IBM Corp). The primary outcome analysis was to evaluate the impact of treatment188
allocation (exenatide or placebo) on the difference between MDS-UPDRS part 3 scores in the189
practically defined “OFF” state at 60 weeks follow up (i.e. after any possible symptomatic effects of190
exenatide should have washed out). The analysis used a regression (ANCOVA, analysis of co-191
variance) approach to adjust for stratification factors (Hoehn and Yahr stage) and baseline raw MDS-192
UPDRS part 3 values. Using previously collected pilot data9 and using a two-sided 5% significance193
level, we estimated a sample size of 60 patients would be required to detect a difference of 5.8194
MDS-UPDRS points between the 2 groups. The calculations were based on a common standard195
deviation of 13, 90% power and an overall type 1 error rate of 5%. In addition, a correlation of 0.85196
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was assumed between the baseline and follow up MDS-UPDRS measurements. All efficacy analyses197
were based on a modified intention-to-treat principle and included all patients who completed any198
post randomisation follow up assessments.199
Differences in continuous motor and non-motor outcome measures in the ON medication state were200
estimated using the same regression approach adjusted for stratification factors (Hoehn and Yahr201
stage) and baseline scores and were additionally adjusted for any change from baseline in LED to202
account for the possible confounding effect of PD medication changes during the trial. Comparison203
of gastrointestinal (GI) adverse events between treatment groups were performed using chi-squared204
tests. Further exploration to ascertain whether there was any relationship between observed205
treatments effects and possible confounding factors such as weight loss and change in LED were206
performed using Pearson’s correlation. A post-hoc exploratory analysis on the primary outcome207
(MDS UPDRS part 3 Off medication scores) additionally adjusted for change from baseline in LED was208
also subsequently conducted to address the possibility that differential increases in LED may have209
confounded motor assessments even in the OFF medication state.210
Statistical parametric mapping (SPM 12, Wellcome Department of Imaging Neuroscience) was used211
to perform a quantitative analysis of the Datscan data. Baseline and delayed images for each subject212
were smoothed and coregistered before spatial normalisation into Montreal Neurological Institute213
space via a Datscan template. Using a fully flexible model, and following image scaling, differences in214
loss of Datscan uptake between baseline and 60 week scans according to randomisation allocation215
were assessed with a univariate ANCOVA, adjusting for baseline differences in Datscan signal, Hoehn216
and Yahr stage and change in LED at 60 weeks. Further analysis was also performed to assess the217
differences in the changes between the two allocations. The resulting statistical parametric maps218
were masked to limit differences to bilateral caudate and putamen regions at a height threshold of219
P<0.01 uncorrected for multiple comparisons, and an extent threshold of 10 voxels.220
Role of funding source221
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The funder of the study (MJFF) had no role in the data collection, data analysis, or in the writing of222
the report. The funder did make helpful comments in the original study design, as well as in the data223
interpretation at a post trial feedback meeting. A planned interim analysis was performed after 60224
subjects completed 24 weeks follow up. The change in the MDS-UPDRS Part 3 score between225
baseline and 24 weeks was compared between placebo and exenatide treated groups. The analysis226
was performed by the trial statistician at UCL CCTU, who ensured the trial team remained blinded to227
treatment allocations. The results of the interim analysis were communicated to the IDMC only and228
recommendations to continue the trial based on recruitment, and adverse event profiles only, were229
communicated to both the TSC and the Michael J Fox Foundation who remained blinded to230
individual treatment allocation. All authors had full access to all of the data in the study, and TF had231
responsibility for the final decision to submit the report for publication.232
RESULTS233
Between 18 June 2014, and March 13 2015, 68 patients were screened for eligibility, having234
completed telephone pre-screening against inclusion/exclusion criteria. Of these, 62 underwent235
randomisation to either exenatide or placebo (Figure 1). Baseline characteristics of all patients236
included in the final analysis are presented in Table 1. Patients randomly allocated to exenatide were237
slightly older, had higher baseline MDS-UPDRS part 3 scores and had lower LED. Based on238
questionnaires and collection of empty drug vials at each visit, treatment compliance with study239
drugs was judged to be excellent for all patients (58 patients reported not missing a single dose).240
At 60 weeks (end of the 12 week washout period), patients in the placebo group had declined by 2.1241
(95%CI -0.6, 4.8) points in the MDS-UPDRS Part 3 OFF medication state while the exenatide group242
improved by 1.0 (95%CI -2.6, 0.7) - conferring a significant advantage of 3.5 points favouring the243
exenatide group (95%CI -6.7, -0.3, p=0.0318) (Table 2 and Figure 2). At 48 weeks (end of the study244
drug exposure period), the placebo group had declined by 1.7 (95%CI -0.6, 4.0) points while the245
exenatide group improved by 2.3 (95%CI -4.1, -0.7) points, resulting in a significant advantage of 4.3246
points (95%CI -7.1, -1.6, p=0.0026) compared to the placebo group. There were no statistically247
12
significant differences in MDS-UPDRS part 1,2 and 4, nor in the MDS-UPDRS part 3 in the ON248
medication state (Table 2). There was only 1 participant who had missing data for the 60 week visit,249
therefore no sensitivity analyses for the primary outcome were performed.250
Table 3 presents the data for the remaining secondary outcome measures. There were no251
statistically significant differences in the Mattis-DRS2, MADRS, UDysRS, NMSS, PDQ39 summary252
index and EQ5D-3L, nor were there differences in the timed motor tests or Hauser diaries between253
exenatide and placebo treated groups.254
Although there was no significant difference in total LED at 60 weeks between the exenatide and255
placebo treated groups, patients treated with exenatide had a mean 19.4mg higher increase in LED256
at the end of the trial compared with placebo. To address this as a possible unanticipated257
confounding effect on the primary outcome, a post hoc exploratory analysis additionally adjusting258
for differences in LED from baseline was performed. This showed that the exenatide treated group259
maintained a significant advantage of 3.6 MDS-UPDRS part 3 points in the off medication state (95%260
CI -6.8 to -0.4, p=0.0294) at 60 weeks and 4.4 points (95 CI -7.2 to -1.6, p=0.0023) at 48 weeks261
compared to the placebo group. There was no significant correlation between the change in LED and262
change in the primary outcome (rho =0.17, p= 0.3588).263
Figure 3 presents the Datscan data analysis. SPM analysis contrasted to show regions with264
decreased Datscan binding between the first and the second scan showed significant declines in265
both groups. The contrasts to show differences in rate of decline between groups, (adjusted for266
baseline scan differences, Hoehn and Yahr stage and change in LED at 60 weeks) height thresholded267
at p<0.01 uncorrected with an extent threshold of 10 voxels, indicated a reduced rate of decline of268
Datscan binding in the exenatide group compared to the placebo group in the right putamen (x, y, z:269
22, 8, 22; T= 2.98, 24voxels), p=0.0018 (uncorrected); left putamen (x, y, z: -26, -18, 10; T=2.76, 12270
voxels), p=0.0034 (uncorrected); and right caudate (x, y, z: 26, 20, 6; T=3.83, 10voxels), p=0.0001271
(uncorrected).272
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The median peak serum exenatide concentration in patients randomised to exenatide was273
543.3pg/ml, and was undetectable in the placebo group. Exenatide patients had median CSF levels274
11.4pg/ml at 12 weeks and 11.7pg/ml at 48 weeks, while all placebo patients had CSF levels below275
the limit of the assay specificity.276
There were an equal number of adverse effects in both groups (Table 4). Weight change occurred in277
both groups but was more common in the exenatide treated group. At 48 weeks patients in the278
exenatide group lost a mean of 2.6kg (95% CI -4.0 to -1.2) in comparison to patients in the control279
group who lost 0.6kg (95% CI -1.9 to 0.8). There was no significant correlation between the degree280
of weight loss and change in the primary outcome (rho =0.30, p= 0.0986). Other GI symptoms281
associated with exenatide occurred in both groups, however there was no statistically significant282
association between the presence/absence of weight loss/ nausea/ loss of appetite/ abdominal pain283
and treatment allocation X2(1)= 0.388, p= 0.5330. There were 8 serious adverse events; 6 occurred in284
the exenatide group and 2 in the placebo group though none were judged to be related to the study285
interventions. There were no other clinically relevant changes in biochemical indices or vital signs.286
Three patients discontinued the study drug prior to 48 weeks but continued follow up assessments287
as per protocol. 1 patient in the exenatide group had asymptomatic hyperamylasemia at 12 weeks288
(pre-defined as a rise greater than 50% above baseline level and the laboratory reference range) and289
the study drug was withdrawn; 2 patients in the placebo group discontinued injections after 9 and290
36 weeks due to worsening anxiety and dyskinesia respectively. An emergency unblinding291
procedure was required for 1 patient in the placebo group who developed pancreatic cancer shortly292
following the end of the trial monitoring period.293
DISCUSSION294
In this study, moderate severity PD patients treated with exenatide for 48 weeks had a statistically295
significant advantage of 4.3 points on the MDS-UPDRS Part 3 in the practically defined OFF296
medication state compared with placebo, that persisted as a statistically significant 3.5 point297
advantage 12 weeks after stopping exenatide. There were no significant differences in the scores of298
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MDS-UPDRS Part 1, 2 and 4, and in assessments of cognition (Mattis-DRS2), mood (MADRS),299
dyskinesia (UDysRS), non-motor symptoms (NMSS) and quality of life (PDQ39 summary index and300
EQ5D-3L). Adverse events were not significantly different between the 2 groups and were not301
significantly related to change in motor scores. The study exploited the ready availability of patients302
at the moderate stages of PD, and utilised the fluctuating nature of symptom severity according to303
dopaminergic treatment to judge disease progression by performing all assessments in the early304
morning in the “practically defined OFF-medication state”. Patients with moderate stage PD with305
wearing off phenomenon were recruited in preference to de novo or “early” stage PD in part to;306
minimise inclusion of patients with atypical forms of parkinsonism; to facilitate speed of recruitment307
and minimise the number of necessary recruiting centres hence reducing costs; to minimise the risk308
of differential dropout among treatment naive patients receiving placebo; and to limit floor effects309
on rating assessment scales.310
The simple washout trial design we chose also enabled rapid and cost efficient data collection in311
comparison to more complex and expensive pivotal trial designs such as “Delayed start”,312
“Randomised withdrawal” or “Long term simple” approaches. The study was a single centre study313
which eliminated inter-site variability in data collection, and potentially facilitated the detection of314
significant effects despite the small sample size, and had an extremely low dropout rate (only 1.7%315
of data was missing for the primary outcome). Patients were also permitted to seek medication316
adjustments via their treating clinicians throughout the trial, similar to routine clinical practice in PD,317
which may have also contributed to patient retention.318
Exenatide was well tolerated in this patient group, who reported its previously recognised adverse319
effects including gastrointestinal symptoms and injection site reactions in similar frequencies to320
previously reported diabetes trials14, none of which affected compliance. Early observational studies321
have suggested that exenatide may be associated with pancreatic cancer however more recent322
studies have found no significant association15. Asymptomatic hyperamylasaemia was reported in323
one patient treated with exenatide necessitating drug withdrawal. Exenatide can induce amylase324
secretion in vitro and increased amylase levels have been reported in patients with Type 2 diabetes325
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treated with similar agents16, and this seems a possible explanation (although the contribution of326
other co-morbid conditions cannot be excluded). Patients lost a mean of 2.6kg which reversed on327
drug cessation. Excessive weight loss (>10% of body mass index during a 12 week interval)328
necessitated temporary withdrawal of the study drug in only 1 patient (assigned to placebo).329
Our study had some limitations. Firstly, in order to ensure preservation of blinding of the rating of330
PD severity, we specified that recording of adverse events and measurement of vital signs and331
weight was performed by independent clinicians, however there remains the possibility that patients332
might have been partially unblinded to their treatment allocation as a result of adverse effects333
(though injection site reactions were similar across both groups). In addition the small size of our334
study meant that despite randomisation, with a block design according to Hoehn & Yahr status, the335
exenatide group had MDS-UPDRS Part 3 scores 5.7 points higher at baseline, while being on 51.6mg336
lower LED than the placebo group, confirming the necessity that these baseline differences were337
adjusted for in the primary analysis. Our statistical analyses suggest that none of the differences in338
our outcome measures are however explicable by differences in adverse events, baseline disease339
severity or adjustment to conventional PD medications.340
To allow us to recruit patients already treated with dopaminergic replacement, we were compelled341
to use the practically defined off-medication MDS UPDRS part 3 scores as our primary outcome342
measure. While this provides a better insight into disease severity than on-medication scores, it is343
possible that additional variability in scores may relate to differences in timing since last PD344
medication, despite the consistent instructions given to patients, and all assessments being done at345
consistent times in the morning. This is of particular importance since the differences we observed in346
off-medication scores were not supported by statistically significant differences in our clinical347
secondary outcome measures. This is likely to be due in part to the major effects of dopaminergic348
replacement on any scores assessed in the on-medication state, (which reflects the usual situation of349
patients). Whether the lack of change in the off-medication timed tests or diaries relate to350
differences in the sensitivity or precision within these measures, and the small sample size recruited351
in the trial, or the stage of disease of the population selected for study needs to be further explored.352
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Interestingly, in this patient population, there was little evidence of any placebo effect in the control353
group. In contrast, among exenatide treated patients, improvements in MDS-UPDRS part 3 scores354
were already detectable at the 12 week time-point suggesting that this agent might have355
symptomatic effects on PD. Furthermore, the advantage seen in the exenatide group at 48 weeks356
was greater than the advantage seen by the 60 week time-point also potentially indicative of a357
symptomatic effect. Nevertheless, the persisting advantage seen at 60 weeks makes it impossible to358
exclude the possibility that exenatide exposure has a longer lasting impact on PD severity, above and359
beyond conventional drug effects on dopaminergic receptors.360
The demonstration that exenatide might have novel symptomatic effects in PD is an important361
discovery in the treatment of this disease. Pre-clinical studies suggest exenatide can normalise362
dopaminergic function in lesioned rodents5,17, but whether symptomatic effects relate to363
improvement in functioning in surviving dopaminergic neurons or via an impact on the364
pharmacokinetics of L-dopa or other dopaminergic therapies requires further study. Beyond the365
identification of an agent which might have novel symptomatic effects in PD, our original aim and366
study design was to assess whether the long lasting advantages we have previously seen in an open367
label trial might be reproducible in a placebo controlled design. Having demonstrated a statistically368
significant difference in our pre-defined primary outcome, further investigation into exenatide as a369
potential disease modifying treatment for PD must also be warranted.370
Distinguishing between long lasting symptomatic effects, and effects which impact on the underlying371
disease pathophysiology have been the subject of previous discussions with no simple solution18,19.372
Most notably, rasagiline, approved for symptomatic treatment in PD, demonstrated inconclusive373
results in a delayed start study designed to assess its effects on disease progression20. In our374
washout design, it is tempting to view persistent benefits detectable after the washout period as375
evidence of disease modification. Although exenatide was undetectable in the serum at 60 weeks,376
we have to consider that the 12 week washout period may have been insufficient to eliminate377
unexpected long-lasting symptomatic effects, contributing to the benefits seen in motor function378
and other modalities. Indeed, PD severity can be altered by symptomatic therapies that induce379
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preservation of healthy behaviours such as exercise which can have long term impacts without380
affecting the underlying neuropathological process21.381
The possibility that exenatide may in fact have neuroprotective effects is supported by robust pre-382
clinical studies which indicate that exenatide affects pathological mechanisms relevant to PD22. This383
includes inhibitory effects on inflammation5,8, promotion of mitochondrial biogenesis23,24,384
neurotrophic effects25,26, stimulation of neurogenesis7, and restoration of neuronal insulin385
signalling27. Whether some or all of these mechanisms contributed to the clinical effects seen in this386
study cannot yet be definitively answered, but it is possible that one or several of these mechanisms387
act in synergy to promote cell survival, preserving and preventing compensatory and maladaptive388
responses respectively.389
Our Datscan analysis used statistical parametric mapping, which is a modern approach for the390
statistical analysis of imaging changes that can also allow for adjustment of baseline differences28391
and has been used previously in PD clinical trials29. Although overall uptake of Datscan declined in392
both groups, a quantitative analysis performed using SPM suggests a possible reduced rate of393
decline in the binding in the exenatide group. However, given that this signal was only detectable at394
uncorrected height thresholds of p=0.0034 or less, this data would benefit from larger confirmatory395
studies, and/or recruiting patients at an earlier disease stage when the rate of change of Datscan396
uptake is greater30, making group differences more readily detectable.397
We have shown that 12 months of treatment with exenatide has a statistically significant impact on398
the MDS UPDRS Part 3 in the practically defined OFF state, however it did not appear to have a399
statistically significant impact on PD severity or quality of life above and beyond that delivered by400
dopaminergic replacement. Longer term exposure using a “long-term simple”, multi-site trial design401
will be necessary to determine the long term consequences of exenatide treatment on daytime402
function in PD and specifically whether it can delay the development of dopa-refractory symptoms in403
PD. Furthermore, since the development of exenatide, additional GLP-1 receptor agonists have been404
developed based either on the structure of exendin-4 or human GLP-1. Although comparative405
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clinical efficacy data to support the use of one agent against another are few, there are some studies406
which suggest significant differences in glycaemic control and frequency of adverse events between407
agents in diabetes trials31,32, and preliminary data indicate that some may exert greater408
neuroprotective effects than others33,34. While the current study has also confirmed for the first time409
that exenatide administered at a dose licensed for treatment in Type 2 diabetes, can cross the blood410
brain barrier in humans and can access the CSF in concentrations equivalent to those in pre-clinical411
PD models associated with advantageous outcomes6,25, further studies investigating the safety,412
efficacy and CNS penetration of other members of this drug class, in parallel with mechanism of413
action studies will help to clarify the eventual role that GLP-1 receptor agonists might play in PD.414
Furthermore the potential relevance of these agents to other neurodegenerative disorders (such as415
Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s disease, multiple sclerosis) and416
other neurological diseases (cerebrovascular disorders, traumatic brain injury)32, is the subject of417
ongoing preclinical studies/ clinical trials.418
In conclusion, we have replicated the findings from our previous open label study and demonstrated419
that exenatide treatment is associated with positive and persistent effects on the practically defined420
off-medication motor scores. Whether this drug acts as a novel symptomatic agent or whether it421
also influences compensatory responses/behaviours, or indeed has neuroprotective effects on the422
underlying pathology still remains uncertain, but nevertheless there is now a strong indication that423
this group of drugs may play a useful role in the future treatment of PD patients.424
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455
Figure legends456
Figure 1. Following randomisation, 2 patients withdrew from the study prior to the first follow up (12457
weeks); 1 patient from the group randomised to exenatide was unable to tolerate OFF medication458
assessments and 1 patient from the placebo group withdrew consent. Given that these individuals459
therefore could not contribute any data to the primary outcome, both were replaced (as per460
protocol) and all of the eventual 60 patients who completed at least the initial 12 week follow up461
were included in the primary analysis. One patient randomised to exenatide was found to have462
asymptomatic hyperamylasemia at 12 weeks and the study drug was withdrawn. Two patients in the463
placebo group discontinued the study drug at 9 and 36 weeks due to worsening anxiety and464
worsening dyskinesia respectively.465
466
Figure 2 (a). MDS-UPDRS part III (OFF medication) score by study visit. Data represents mean ± SEM.467
Figure 2(b). Change in MDS-UPDRS part III OFF medication by study visit (data represents mean ±468
SEM)469
470
Figure 3. ANCOVA comparing decline in Datscan binding between placebo and exenatide treated471
groups. Panel A – Placebo group showing reduced Datscan binding in the left caudate, right caudate,472
left putamen. Panel B – Exenatide group showing reduced Datscan binding in the left caudate and473
right caudate. Panel C – Significant clusters derived from the first level of analysis used to perform an474
ANCOVA between placebo and exenatide groups indicating a reduced rate of decline in the right475
caudate, left putamen and right putamen. Panel D – Boxplots showing mean change in Datscan476
binding ratio for the relevant volume of interest. Montreal Neurological Institute of standardized477
space are shown in each slice.478
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Table 1. Patient characteristics at baseline (excludes 2 patients recruited but who did not complete any follow up visits).
Characteristic Exenatide
N = 31
Placebo
N = 29
Age - years (SD) 61.6 (8.2) 57.8 (8.0)
Gender
Female – no. (%)
Male – no. (%)
9 (29.0)
22 (71.0)
7 (29.1)
22 (75.9)
Age at diagnosis – years (SD) 55.9 (7.9) 52.2 (7.7)
Duration of diagnosis at baseline - years (SD) 6.4 (3.3) 6.4 (3.3)
Hoehn & Yahr Stage
Stage 1.0 – 2.0 – no. (%)
Stage 2.5 – no. (%)
29 (93.5)
2 (6.5)
29 (100.0)
0 (0.0)
MDS-UPDRS Part3 at baseline OFF medication – points (SD) 32.8 (9.7) 27.1 (10.3)
Levodopa equivalent dose – mg (SD)* 773.9 (260.9) 825.7 (215.0)
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Table 2. MDS-UPDRS scores between baseline and Week 60.
Baseline 12 weeks 24 weeks 36 weeks 48 weeks Change,
Baseline to 48
weeks
Adjusted
difference,
baseline to 48
weeks
60 weeks Change,
Baseline to 60
weeks
Adjusted
difference,
baseline to 60
weeks
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (95% CI) Mean (95% CI)
P value
Mean (SD) Mean (95% CI) Mean (95% CI)
P value
In OFF medication state
MDS-UPDRS Part 3
Exenatide 32.8 (9.7) 30.3 (10.9) 30.6 (10.8) 31.2 (11.3) 30.2 (11.1) -2.3 (-4.1, -0.7) -4.3 (-7.1, -1.6)
0.0026
31.9 (12.0) -1.0 (-2.6, 0.7) -3.5 (-6.7, -0.3)
0.0318Placebo 27.1 (10.3) 27.6 (11.8) 28.5 (11.0) 28.6 (9.5) 28.8 (10.8) 1.7 (-0.6, 4.0) 29.2 (12.0) 2.1 (-0.6, 4.8)
In ON medication state
MDS-UPDRS Part 1
Exenatide 9.8 (4.8) 8.6 (4.2) 8.3 (3.6) 8.0 (4.2) 8.8 (4.4) -1.0 (-2.4, 0.4) -1.3 (-3.4, 0.8)
0.21
9.3 (4.0) -0.5 (-2.0, 1.1) -1.2 (-3.2, 0.8)
0.22Placebo 9.2 (3.8) 8.7 (5.0) 8.9 (4.4) 9.3 (4.6) 9.7 (5.6) 0.5 (-1.2, 2.2) 10.1 (5.3) 0.7 (-0.8, 2.3)
MDS-UPDRS Part 2
Exenatide 12.5 (6.7) 10.9 (7.0) 11.2 (7.4) 11.7 (7.8) 11.7 (6.3) -0.7 (-2.1, 0.7) -0.6 (-2.7, 1.5)
0.58
11.6 (6.6) -0.8 (-2.2, 0.6) -0.6 (-2.7, 1.5)
0.55Placebo 10.7 (5.3) 10.2 (5.6) 11.1 (6.0) 10.1 (6.1) 10.8 (5.6) 0.1 (-1.6, 1.9) 11.0 (6.7) 0.2 (-1.4, 1.8)
MDS-UPDRS Part 3
Exenatide 19.4 (8.4) 19.3 (9.1) 20.4 (9.7) 19.6 (8.8) 20.5 (9.5) 1.1 (-0.8, 3.0) -0.002 (-2.4, 2.4)
0.99
19.9 (10.3) 0.5 (-1.9, 3.0) 0.7 (-2.1, 3.6)
0.61
Placebo 14.4 (8.2) 15.4 (8.3) 16.0 (7.1) 16.7 (7.7) 15.7 (7.1) 1.3 (-0.4, 3.0) 14.5 (7.1) -0.02 (-1.8, 1.8)
MDS-UPDRS Part 4
Exenatide 4.7 (3.1) 4.1 (3.4) 4.2 (2.0) 4.6 (2.5) 4.9 (2.5) 0.3 (-0.9, 1.4) -0.5 (-1.8, 0.9)
0.48
5.2 (2.3) 0.5 (-0.5, 1.6) -0.6 (-2.1, 0.9)
0.42Placebo 5.3 (3.0) 5.8 (2.7) 5.2 (3.2) 5.3 (3.4) 5.6 (3.0) 0.3 (-0.9, 1.5) 6.1 (3.7) 0.7 (-0.7, 2.1)
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Table 3. Scores for Mattis-DRS2, UDysRS, MADRS, NMSS, PDQ-39 Summary index, Keyboard taps in 30seconds, 10m Timed walk, patient diaries, LED and
vital signs between baseline and Week 60 according to randomisation allocation. All scores in ON-medication state. *Higher scores reflect improved status
on these scales.
Domain Baseline 12 weeks 24 weeks 36 weeks 48
weeks
Change
Baseline to
48 weeks
Adjusted difference,
baseline to 48
weeks
60 weeks Change
Baseline to
60 weeks
Adjusted difference,
baseline to 60 weeks
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean
(SD)
Mean
(95% CI)
Mean (95% CI)
P value
Mean (SD) Mean
(95% CI)
Mean (95% CI)
P value
Cognition In ON-medication state
MATTIS Dementia Rating scale *
Exenatide 138.0 (5.0) 139.0 (6.1) 139.5 (4.2) 140.3
(3.7)
139.7
(4.1)
1.7
(0.4, 2.9)
0.4 (-1.0, 1.9)
0.57
139.9 (3.6) 1.9
(0.6, 3.1)
0.8 (-0.9, 2.5)
0.32
Placebo 139.8 (3.7) 140.3 (3.1) 139.7 (5.8) 140.3
(4.1)
140.2
(3.9)
0.4
(-0.6, 1.5)
140.2 (4.6) 0.4
(-1.1, 1.8)
Dyskinesia
Unified Dyskinesia Rating Scale
Exenatide 5.4 (7.9) 5.4 (8.0) 4.4 (6.5) 5.6 (7.9) 5.1 (7.1) -0.3
(-2.3, 1.8)
-0.8 (-3.6, 1.9)
0.53
6.2 (7.2) 0.8
(-1.7, 3.3)
-1.6 (-5.1, 1.8)
0.35
Placebo 7.3 (9.4) 6.8 (9.7) 6.9 (9.8) 6.8 (9.9) 7.4
(10.7)
0.1
(-1.7, 1.8)
9.0 (12.4) 1.7
(-0.8, 4.2)
Mood
MADRS
Exenatide 4.1 (3.7) 3.4 (3.5) 2.2 (1.8) 2.7 (3.1) 2.5 (2.7) -1.6
(-3.4, 0.07)
-1.4 (-3.2, 0.5)
0.15
2.1 (2.6) -1.6
(-2.7, -0.4)
-0.9 (-2.2, 0.3)
0.15
Placebo 3.7 (3.0) 2.9 (3.8) 3.5 (4.4) 3.9 (4.4) 3.8 (4.2) 0.2
(-1.8, 2.2)
2.8 (2.6) -0.9
(-2.3, 0.5)
Non motor
symptoms NMSS
Exenatide 24.6 (19.8) 17.7 (15.4) 16.4 (12.4) 16.5
(10.3)
19.7
(12.4)
-4.9
(-11.6, 1.8)
-4.0 (-11.8, 3.8)
0.30
22.3 (14.2) -2.3
(-9.6, 5.1)
-3.3 (-11.7, 5.1)
0.43
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Placebo 28.3 (24.7) 22.0 (22.4) 22.1 (20.2) 23.1
(21.6)
25.8
(22.8)
-2.5
(-9.5, 4.6)
27.6 (23.3) -1.5
(-9.0, 6.0)
Quality of
Life PDQ-39 Summary index
Exenatide 19.9 (13.7) 17.1 (10.7) 16.8 (10.6) 17.2
(11.4)
18.7
(12.7)
-1.2
(-4.7, 2.3)
-1.7 (-5.6, 2.1)
0.38
18.4 (11.1) -1.5
(-5.4, 2.4)
-3.3 (-8.0, 1.5)
0.17
Placebo 21.1 (13.0) 17.8 (10.9) 18.6 (14.2) 20.5
(15.6)
20.1
(12.8)
-1.1
(-4.2, 2.1)
22.2 (14.8) 0.3
(-3.4, 4.0)
EQ5D Index*
Exenatide 0.71 (0.20) 0.72 (0.17) 0.76 (0.14) 0.81
(0.14)
0.74
(0.23)
0.03
(-0.07,
0.12)
0.06 (-0.03, 0.15)
0.21
0.72 (0.18) 0.005
(-0.08,
0.09)
-0.003 (-0.09, 0.09)
0.95
Placebo 0.79 (0.16) 0.72 (0.19) 0.77 (0.14) 0.75
(0.16)
0.74
(0.14)
-0.05
(-0.10,
0.002)
0.75 (0.14) -0.06
(-0.12,
0.01)
EQ5D VAS (%)
EQ5D VAS*
Exenatide 73.6 (14.5) 72.3 (13.7) 71.5 (15.6) 71.4
(16.6)
70.1
(15.6)
-3.2
(-8.9, 2.5)
6.9 (-1.0, 14.8)
0.08
68.1 (14.4) -5.6
(-12.2, 1.1)
5.3 (-3.0, 13.5)
0.21
Placebo 74.5 (16.0) 68.6 (13.2) 68.5 (18.7) 69.0
(19.7)
64.7
(20.5)
-9.3
(-15.4, -
3.1)
65.1 (20.2) -10.6
(-16.4, -
4.8)
Timed
motor tests
In OFF-medication state
Right hand taps in 30sec*
Exenatide 46.5
(9.9)
48.3
(10.7)
48.5
(13.8)
46.9
(12.4)
47.9
(11.2)
1.1
(-2.5, 4.8)
-1.1 (-5.8, 3.6)
0.69
46.6
(12.1)
0.4
(-3.0, 3.8)
1.1 (-4.3, 6.4)
0.64
Placebo 53.9 (13.1) 54.0 (13.0) 52.2 (12.2) 52.9
(11.4)
50.5
(11.0)
-3.1
(-7.8, 1.7)
52.7 (9.8) -1.0
(-4.5, 2.5)
Left hand taps in 30 sec*
Exenatide 47.8
(9.3)
48.8
(9.4)
49.0
(10.5)
48.3
(8.7)
47.7
(9.8)
0.3
(-2.7, 3.3)
-0.9 (-4.8, 2.9)
0.69
47.2 (9.7) -0.6
(-3.8, 2.6)
0.2 (-4.0, 4.4)
0.62
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Placebo 50.6 (11.5) 52.6 (11.8) 50.2 (11.0) 49.9
(10.5)
49.7
(10.2)
-0.9
(-4.6, 2.8)
49.5 (9.7) -0.3
(-3.0, 2.3)
10m Timed walk (sec)
Exenatide 17.2 (4.5) 16.2 (7.8) 17.3 (9.6) 16.7 (8.1) 17.4
(11.1)
0.2
(-3.1, 3.4)
0.8 (-4.6, 6.1)
0.69
19.5 (16.5) 2.5
(-2.5, 7.5)
-0.7 (-4.2, 2.8)
0.78
Placebo 17.1 (6.3) 16.2 (5.4) 16.4 (7.1) 14.8 (4.8) 16.6
(8.8)
-0.5
(-2.9, 1.9)
19.1 (16.0) 1.8
(-2.5, 6.1)
In ON-medication state
Right hand taps in 30sec*
Exenatide 52.8 (11.7) 53.0 (12.0) 51.5 (11.9) 51.5
(12.9)
51.3
(12.9)
-1.5
(-7.0, 3.9)
-3.2 (-8.4, 2.1)
0.28
52.6 (11.4) -0.7
(-5.7, 4.3)
-3.4 (-9.6, 2.8)
0.23
Placebo 59.1 (14.5) 59.3 (11.6) 59.3 (12.4) 59.7
(10.0)
57.6
(10.3)
-1.3
(-5.9, 3.4)
58.7 (11.5) 0.4
(-2.9, 3.7)
Left hand taps in 30 sec*
Exenatide 52.9 (10.0) 49.8 (12.7) 50.6 (10.1) 50.5
(10.8)
49.0
(10.2)
-4.1
(-7.4, -0.9)
-1.2 (-5.2, 2.8)
0.18
50.9 (12.0) -2.1
(-5.3, 1.2)
-2.9 (-7.1, 1.4)
0.54
Placebo 56.6 (13.0) 56.3 (12.1) 55.8 (10.3) 56.3
(10.0)
54.6
(11.9)
-2.2
(-5.6, 1.2)
54.1 (10.8) -1.1
(-3.4, 1.2)
10m Timed walk (sec)
Exenatide 15.2 (2.7) 14.9 (3.4) 14.7 (3.3) 14.4 (3.3) 15.1
(5.5)
-0.03
(-1.5, 1.4)
-1.5 (-4.6, 1.6)
0.61
15.0 (5.8) -0.1
(-1.6, 1.4)
0.3 (-0.9, 1.6)
0.35
Placebo 14.7 (3.1) 14.3 (3.2) 14.4 (3.7) 14.2 (3.3) 13.6
(3.0)
-1.1
(-1.8, -0.4)
15.3 (7.5) 0.6
(-2.4, 3.7)
Patient
Diaries Hauser Diary - Asleep (%)
Exenatide 30 29 30 31 30 28
Placebo 26 26 27 27 27 25
30
Hauser Diary - OFF (%)
Exenatide 17 14 15 12 16 18
Placebo 20 20 17 19 20 22
Hauser Diary-On without dyskinesia (%)
Exenatide 49 53 48 52 49 50
Placebo 49 50 50 48 47 47
Hauser Diary- On with non-troublesome dyskinesia (%)
Exenatide 3 3 5 4 5 5
Placebo 3 2 5 3 4 4
Hauser Diary- On with troublesome dyskinesia (%)
Exenatide 1 4 2 1 1 5
Placebo 1 2 1 3 2 3
Vital signs Blood Pressure - Mean Arterial Pressure (mmHg)
Exenatide 95.4 (15.8) 95.8 (12.1) 96.2 (11.5) 93.8
(12.2)
96.8
(11.0)
1.4
(-2.7, 5.6)
95.8 (13.6) 0.4
(-4.2, 4.9)
Placebo 94.2 (7.9) 93.1 (11.2) 93.8 (9.1) 93.8 (9.5) 95.0
(9.6)
0.8
(-2.2, 3.7)
95.2 (7.6) 1.3
(-2.1, 4.7)
Weight (kg)
Exenatide 81.8 (16.6) 80.0 (16.3) 79.3 (16.5) 78.1
(15.9)
79.2
(16.1)
-2.6
(-4.0, -1.2)
80.9 (16.6) -0.9
(-2.6, 0.7)
31
Placebo 80.8 (12.9) 80.1 (14.3) 80.2 (14.0) 79.5
(13.6)
80.2
(13.3)
-0.6
(-1.9, 0.8)
80.5 (14.3) -0.09
(-1.5, 1.3)
Levodopa
Equivalent
doses (LED)
Levodopa Equivalent dose (mg)
Exenatide 773.9
(260.9)
804.5
(288.3)
851.7
(336.5)
849.3
(368.6)
895.6
(337.7)
121.8
(47.7,
195.8)
906.1
(328.8)
132.2
(61.5,
203.0)
Mean
Change
per visit
↑30.6 ↑47.2 ↓2.4 ↑46.3 ↑10.5
Placebo 825.7
(215.0)
828.8
(225.4)
897.5
(225.0)
883.3
(218.9)
913.0
(243.4)
87.3
(-2.4,
177.1)
942.7
(235.2)
112.6
(40.7,
184.4)
Mean
Change
per visit
↑3.1 ↑68.7 ↓14.2 ↑29.7 ↑29.7
Medication PD medication by drug class (n=)
Exenatide
L-DOPA
DA agonist
MAO-B
31
24
17
31
25
17
31
24
17
31
24
17
31
24
17
31
24
17
Placebo
L-DOPA
DA agonist
MAO-B
29
23
13
29
23
13
29
25
14
29
25
14
29
25
15
29
25
15
32
Table 4. Serious adverse events and adverse events reported (per event) according to randomisation allocation.
Exenatide Placebo Total
Serious Adverse Event
Fall* 2 0 2
Atrial flutter** 1 0 1
Acute urinary retention 1 0 1
Collapse 1 0 1
Significant weight loss*** 0 1 1
Faecal impaction 0 1 1
Postural hypotension 1 0 1
Total 6 2 8
Adverse Event
Injection site reaction 27 26 53
Weight loss from baseline**** 24 18 42
0-2kg 11 10
2-4kg 2 3
>4kg 11 5
Nausea 16 10 26
Other pain 13 11 24
Constipation 12 11 23
Increased OFF time 8 12 20
Diarrhoea 8 6 14
Weight gain from baseline**** 7 11 18
Lower urinary tract symptoms 6 7 13
Sleep disorder 3 6 9
Abdominal pain 5 3 8
Increased dystonia 3 5 8
Back pain 2 5 7
Upper respiratory tract infection 5 3 8
Dyskinesia 2 3 5
Loss of appetite 3 1 4
Anxiety 2 1 3
Freezing 1 2 3
Urinary tract infection 0 3 3
Hyperamylasemia 1 1 2
Rash 1 1 2
Vomiting 2 0 2
Fever 1 0 1
33
Worsening tremor 0 1 1
Miscellaneous 64 46 110
Total 216 193 409
*One fall occurred in an individual prior to randomisation
**Occurred prior to first dose of exenatide
*** Defined as loss of weight of >10% BMI in 12 week period
****After 48 weeks exenatide / placebo exposure- (figures for weight change are presented per patient rather than per
event).
Screened
N=68
Eligible
N=65
Ineligible N=3
• Type 2 diabetes
• Mattis DRS-2 score <120
• Concomitant disease
Placebo
N=30
Analysed
N=29
Exenatide
N=32
Analysed
N=31
Randomised
N=62
Withdrew consent
N=3
Withdrew before 12
weeks
N=1
Discontinued Exenatide
N=1
Withdrew before 12
weeks
N=1
Discontinued Placebo
N=2
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